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Abstract
Background: Carrageenan is a traditional ingredient that has been widely used in the food industry. In the present
study, we propose a hypothesis that carrageenan is a conditional inflammatory agent. When the intestinal tract is in
an “unhealthy” state such as that during bacterial infection or acute inflammation, carrageenan can synergistically
enhance the inflammatory response.
Methods: BALB/C mice received κ-carrageenan via intragastric administration prior to the induction of oxazolone
colitis. Weight changes, survival rate, histologic change, secretion of inflammatory cytokines, ratio of regulatory T
cells (Tregs) in peripheral blood, and expression of genes and proteins involved in inflammation and cell proliferation
in the colonic mucosa were examined.
Results: Intragastric administration of κ-carrageenan to BALB/c mice prior to the induction of oxazolone colitis resulted
in an aggravation of body weight loss, a decrease in the survival ratio, aggravation of colonic inflammation, and decrease
in the ratio of CD4 + CD25+/CD4+. The secretion of interleukin-4 (IL-4), interleukin-10 (IL-10), tumor necrosis factor-α
(TNF-α), and interleukin-6 (IL-6) also significantly increased after κ-carrageenan administration. κ-Carrageenan,
together with oxazolone, suppressed the expression of forkhead box p3 (FOXp3) and increased the expression of
Toll-like receptor 4 (TLR4), Nuclear factor-κB (NF-κB), and proliferating cell nuclear antigen in the colonic mucosa.
These results were confirmed by qRT-PCR and western blot analyses at the molecular and protein levels, respectively.
Conclusions: κ-Carrageenan aggravated oxazolone-induced intestinal inflammation in BALB/c mice. This effect is
associated with an activation of the TLR4-NF-κB pathway, a decreased ratio of Tregs, and the induction of Th2-dependent
immune responses.
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Background
Carrageenan, a high-molecular weight saccharide, is
used widely as a thickener, stabilizer, emulsifier, and
texturizer in a variety of processed foods (including in-
fant formula, whipped cream, cottage cheese, ice cream,
and nutritional supplements) and other products (i.e.,
pharmaceuticals, cosmetics, and toothpaste) [1–3]. Several
international agencies have earlier reported that carra-
geenan is safe for human consumption [4, 5]. However, in-
vestigators later demonstrated that carrageenan induces
gastrointestinal ulcerations and cancer in animal models
[2, 4]. Carrageenan has been widely used in experimental
models of inflammation to assess the activity of anti-
inflammatory drugs and to study mediators of inflamma-
tion [6]. Therefore, the concept of safety of carrageenan
has remained highly controversial.
Current research studies on carrageenan have mainly fo-
cused on its effects at the organismal and cellular levels.
Animal models such as rats [6], guinea pigs [7], pig [8],
mouse [9], and rhesus monkeys [10] have demonstrated
that carrageenan induces colorectal tumors and ulcerative
colitis. However, several international agencies have con-
cluded that carrageenan is harmless [4, 5]. The US Food
and Drug Administration (FDA) has declared food-grade
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carrageenan as generally recognized as safe (GRAS) for
use as a food ingredient [11]. Tobacman et al. conducted
extensive research studies to evaluate the safety of carra-
geenan at the cellular level [2, 12–19]. They observed that
exposure of human intestinal epithelial cells to food-grade
carrageenan triggered a distinct inflammatory response
via the activation of Bcl10 in the NF-κB pathway [20],
as well as up regulation of interleukin-8 (IL-8) secretion
[16, 20], and identified that the Toll-like receptor 4
(TLR4) is the surface membrane receptor for carra-
geenan in human colonic epithelial cells. Bernard et al.
observed that carrageenan induces tumor necrosis factor
alpha (TNF-α) production in human monocytes [21].
Although an upregulation of inflammatory cytokines in
human cells occurs following food-grade carrageenan
exposure, we found that the increase was actually low,
only 2–3-fold higher than that observed in the blank con-
trol [16, 20]. Is this difference in expression level enough
to cause a strong inflammatory reaction in vivo? Although
lipopolysaccharides, which are highly proinflammatory
molecules, can increase the secretion of IL-8 and TNF-α
in macrophages by a dozen- to a hundred-fold [22], the
inflammatory mechanism of carrageenan remains elusive.
In our previous studies, we observed that λ-carrageenan
enhances the LPS-induced production of IL-8 at the cellu-
lar level [23]. Moreover, when differentiated human
colonic epithelial cells were co-cultured with macrophage
cells, the epithelial monolayers were significantly and eas-
ily damaged by carrageenan. Based on these earlier find-
ings, we hereby propose the hypothesis that carrageenan
is a conditional inflammatory agent. When the intestinal
tract is in an “unhealthy” state such as that during bacter-
ial infection or acute inflammation, carrageenan can syn-
ergistically enhance the inflammatory response.
Therefore, in the present study, an oxazolone (OXA)-
induced mild intestinal inflammation model was devel-
oped to investigate whether κ-carrageenan can enhance
the inflammatory responses of the gut with acute inflam-
mation. Furthermore, the mechanism underlying this
inflammatory response was also investigated in relation
to the TLR4 pathway.
Methods
Animals
Seven-week-old male and female BALB/c mice with
weights ranging from 20-25 g were purchased (SCXK
2012–0001, Beijing Weitong Lihua Experimental Animal
Technology Co., Ltd.), housed in the animal center of
Ningbo University Medicine College (Ningbo, China), and
used in the present study. Five same-sex mice were
housed in a cage and maintained under a 12-h light/12-h
dark cycle (08:00 AM lights on) with food and water pro-
vided ad libitum. Housing and experimental environments
were temperature- and humidity-controlled (21 ± 2 °C and
approximately 60 %, respectively). All mice were allowed
to habituate to the housing environment for 3 days prior
to gavage administration. All experimental procedures
were performed in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory
Animals, and approved by the Ethical Committee of
Animal Use and Protection of Ningbo University Health
Science Center.
Animal experimental procedure
Eighty mice were divided into eight groups and placed
in clear plastic cages with a mesh top under specific
pathogen-free conditions, with each experimental group
consisting of four males and four females. The experi-
mental groups were designed as follows: the blank group
only received a saline solution; the OXA group was treated
with 150 μL of 1 % OXA; the carrageenan groups were
treated with different concentrations of carrageenan,
namely, the low-dose group (1.7 mg/kg, LOW), medium-
dose group (8.3 mg/kg, MED), and high-dose group
(41.7 mg/kg, HIG); carrageenan +OXA groups received
low, medial, and high doses of carrageenan following by
the administration of OXA and marked as “LOW+OXA,”
“MED+OXA,” and “HIG+ OXA.”
κ-Carrageenan (Sigma Chemical Co., St Louis, MO,
USA) was dissolved in saline with vigorous stirring at 37 °C
and administered at three different doses, 1.7 mg/kg,
8.3 mg/kg, and 41.7 mg/kg by gavage administration.
These doses were decided according to the data of prelim-
inary experiments based on related study [18]. To assess
the synergistic effect of carrageenan on OXA-induced
inflammation, different doses of carrageenan were gavage
administered for two weeks prior to OXA administration.
OXA-induced intestinal inflammation was established
as previously described by Heller et al., with minor mod-
ifications [24]. To presensitize mice, a 2 × 2 cm area of
the abdominal skin was shaved, and 200 μL of OXA [a
3 % (w/v) solution in 100 % ethanol, Sigma-Aldrich, St.
Louis, MO] was smeared 5 days before OXA was admin-
istered. Five days after presensitization (day 0), the mice
were rechallenged intrarectally with 100 μL of 1 % OXA
in 50 % ethanol or only 50 % ethanol (vehicle, Blank
group) under general anesthesia with isoflurane (Baxter,
Deerfield, IL, USA). Intrarectal injection was adminis-
tered with a polyurethane umbilical catheter. To ensure
distribution of the OXA throughout the entire colon,
the mice were held head down in a vertical position for
60 s after injection.
The mice were then monitored for symptoms of diar-
rhea, loss of body weight, and death the next day (day 1).
The mice underwent exsanguination by cardiac puncture
and the collected blood was used to determine the CD4
+CD25+ Treg ratio and cytokine levels by flow cytometry.
The colon was also isolated; one portion was used in
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macroscopic evaluation, whereas the rest was fixed in
paraformaldehyde (Merck, Darmstadt, Germany) or glu-
taraldehyde solution for immunohistochemical and scan-
ning electron microscopy analysis.
Macroscopic evaluation
Macroscopic evaluation of colonic tissues used the fol-
lowing criteria: 0, normal; 1, erythema only; 2, erythema,
slight edema, and small erosions; 3, two or more bleed-
ing ulcers and/or inflammation and/or moderate adhe-
sions; and 4, severe ulceration and/or stenosis with
dilations and/or severe adhesions.
Histological analysis
The colonic tissues were dissected and washed with
Hank's balanced salt solution (containing 10 μg/mL of
gentamicin, 100 U/mL of penicillin, and 100 μg/mL of
streptomycin). The tissues were then fixed in 10 % natural
buffered formalin, embedded in paraffin, cut into tissue
sections (5-μm-thick), and stained with hematoxylin and
eosin (H&E).
Histological examination was evaluated as previously
described [25]. The degree of histologic damage and in-
flammation was graded in a blinded fashion by expert his-
tologists. The following manifestations were included in
the evaluation: the amount of inflammation (0, none; 1,
mild; 2, moderate; 3, severe; and 4, accumulation of in-
flammatory cells in the gut lumen), distribution of lesions
(0, none; 1, focal; 2, multifocal; 3, nearly diffuse; and 4, dif-
fuse), depth of inflammation and layers involved (0, none;
1, mucosa only; 2, mucosa and submucosa; 3, limited
transmural involvement; and 4, transmural), and nature of
mucosal changes (0, none; 1, minimal degeneration; 2,
more degeneration; and 3, more necrosis). The overall
histologic score was the sum of the four manifestations
(maximum score: 15).
Intestinal mucosal morphology
The processing of intestinal segments for scanning elec-
tron microscopy was conducted as described elsewhere
[26]. Briefly, one segment of the tissue sample was fixed
with 2.5 % glutaraldehyde. The segments were washed
twice in phosphate buffer (pH = 7.2) and then post-fixed
in osmium tetroxide (1 % in phosphate buffer, pH = 7.2,
2 h). After a series of dehydration steps in alcohol from
30 % to 100 %, the segments were critical point-dried
(CPD030; BAL-TEC; Balzers; Liechtenstein), mounted
on Al stubs, sputter-coated with gold by using a high-
resolution fine coater (SCD005; BAL-TEC; Balzers;
Liechtenstein), and then examined under a Jeol JSM-
6301 scanning microscope (JEOL Ltd., Musashino,
Tokyo, Japan). Morphological evaluation of the intestinal
mucosal and microvilli was then performed. Scanning
electron microscopic images (×200 magnification) were
analyzed to measure the histological changes on the epi-
thelial cell surface.
Determination of CD4 + CD25 + Treg ratio by flow
cytometry
A total of 2.5 μL of anti-mouse CD3-eFluor450, 0.625 μL
of anti-mouse CD4-PE, 0.625 μL of anti-mouse CD25-
APC (all from eBioscience, California, USA) were added
to 100 μL of peripheral blood. Following incubation at
room temperature in the dark for 15–30 min, 1 mL of
erythrocyte lysis solution was added to the samples and
incubated for 15–20 min. The cells were washed with
2 mL phosphate-buffered saline (PBS) and resuspended
in 500 μL PBS. The cells were then analyzed using a
Beckman Gallios flow cytometer (Beckman Coulter,
Inc., California, USA).
Immunohistochemical analyses
For immunocytochemical analysis, the mouse colonic tis-
sues were fixed with 4 % paraformaldehyde in PBS, embed-
ded in paraffin, and cut into tissue sections (5-μm-thick).
The tissues were blocked with 1 % bovine serum albumin
(BSA, Nacalai tesque) for 60 min at room temperature.
The primary antibodies used in the present study included
anti-TLR4 antibody (1:200, ab22048, Abcam, Cambridge,
UK), anti-NF-κB antibody (1:200, 8242, CST, Danvers,
MA, USA), anti-FOXp3 antibody (1:200, ab54501, Abcam,
Cambridge, UK), and anti-PCNA antibody (1:100, Santa
Cruz Biotechnology, Dallas, TX, USA). Secondary anti-
bodies included goat anti-rabbit IgG (PV-9001, ZSGB-BIO,
Peking, China) and rabbit anti-mouse IgG (PV-9005,
ZSGB-BIO, Peking, China). Negative controls substituted
with non-immunized mouse IgG at the same concentra-
tions as that for each primary antibody were employed.
Images were captured using a Leitz Dialux 22 Microscope
(Leica Microsystems, Wetzlar, Germany) equipped with a
QIcam Fast 1394 camera (QImaging, Surrey, BC, Canada).
The images were analyzed using the software, Image Pro
Plus 6.0 (Media Cybernetics UK, Marlow, UK). The levels
of expression of TLR4, NF-κB, FOXp3, and PCNA were
determined by measuring the positively labeled areas in
relation to the total area.
Analysis of cytokine levels
Serum samples were collected after centrifugation of
blood and stored at −80 °C. The levels of proinflammatory
cytokines, including interleukin IL-6, tumor necrosis fac-
tor (TNF), Th1 (IL-2, interferon IFN-γ), Th2 (IL-4, IL-10),
and Th17 (IL-17) cytokines in each serum sample were
determined by using the BD Cytometric Bead Array
mouse Th1/Th2/Th17 7 cytokine kit (BD BioSciences, NJ,
USA) according to the manufacturer’s instructions. Sam-
ples and standards were analyzed on a FACS Calibur flow
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cytometer (BD BioSciences, NJ, USA). The concentrations
were assessed by using FCAP Array software.
RNA extraction and real-time quantitative reverse
transcription-PCR (RT-qPCR) analysis
Total RNA was isolated from scraped colonic mucosa of
experimental mice using the TaKaRa RNAiso Plus
Reagent (TaKaRa, Dalian, China) following the manufac-
turer’s instructions and then treated with RNase-free
DNase I. Then, 2 μg of total RNA was re-transcribed
into cDNA using a total reaction volume of 40 μL fol-
lowing standard M-MLV reverse transcriptase protocols
(TaKaRa, Dalian, China). The primers of mouse target
genes, including TLR4, NF-κB, FOXp3, and PCNA, as
well as reference genes β-actin, GAPDH, and 18S-rRNA
are listed in Table 1. The corresponding PCR products
were sequenced by an ABI 3730 automated sequencer
(Invitrogen, Carlsbad, CA, USA). To assess PCR effi-
ciency, 10-fold serial dilutions of TLR4, NF-κB, FOXp3,
PCNA, β-actin, Gapdh, and 18S-rRNA plasmid cDNA
were used to generate a standard curve for each assay
plate. The PCR reaction system included 1 μL of cDNA,
0.4 μM of forward and reverse primers, 10 μL of SYBR
Premic Ex Taq II, 7.4 μL of dH2O, as recommended by
the manufacturer of SYBR-Green I (TaKaRa, Dalian,
China). The cycling conditions were 95 °C for 5 min,
followed by 40 cycles of 95 °C for 30 s, 60 °C for 1 min,
and 72 °C for 15 s, which were conducted on a Master-
cycler ep realplex real-time PCR system (Eppendorf,
Hamburg, Germany). By using a standard curve, PCR
efficiency was calculated (Table 1). After the amplifica-
tion, melting curves were obtained by slow heating from
60 °C to 95 °C at increments of 0.5 °C/s and continuous
fluorescence collection, which confirmed that only our
specific product peaks were detected. RT-qPCR analysis
of the samples was conducted as earlier described. Rela-
tive gene expression was analyzed by using the compara-
tive cycle (Ct) value, which was compared using the
relative quantification method. The mRNA expression of
TLR4, NF-κB, FOXp3, PCNA, GAPDH, and 18S-rRNA
were normalized against the expression of β-actin.
Preparation of nuclear extracts
To prepare a whole lysate solution, the collected tissues
were washed twice with ice-cold PBS and lysed in a lysis
buffer (Beyotime, Shanghai, China) that contained 1 mM
of phenylmethylsulfonyl fluoride (PMSF) and a protein
phosphatase inhibitor cocktail (Roche, Basel, Switzerland)
for 10 min on ice. The homogenates were centrifuged at
12,000 rpm at 4 °C for 10 min. Total protein was extracted
from the scraped colonic mucosa of the experimental
mice using a NE-PER nuclear and Cytoplasmic Extraction
kit (Pierce, Rockford, IL, USA), following the manufactur-
er's recommendations. Protein concentration was deter-
mined using a Bio-Rad DC Protein assay reagent (Bio-Rad
Laboratories, Inc., Hercules, CA, USA), following the
manufacturer's instructions.
Western blot analysis
Proteins (30 μg) in the nuclear extracts or in the whole
lysate were separated by 10 % sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE), transferred onto polyvi-
nylidene fluoride (PVDF) membranes, and probed with
antibodies against TLR4, NF-κB, and p65 antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA),
followed by appropriate horseradish peroxidase (HRP)-
linked secondary antibodies (CST). The immunoreactive
proteins were detected by using WesternBright ECL
(Advansta Inc., Menlo Park, CA, USA). The results were
quantified by measuring the band intensity relative to that
of β-actin using the AlphaView™ Software (Alpha Innotech,
San Leandro, CA, USA), and expressing as the relative
intensities.
Statistical analysis
Statistical analyses were performed using the SPSS software,
version 16.0 (SPSS Inc., Chicago, IL, USA). The results were
expressed as means ± SEM. P < 0.05 was considered to indi-
cate statistically significant differences. Macroscopic and
histological score analyses were performed by using the
student’s t-test. Differences in weight loss, cytokine levels,
ratio of Treg (CD4+CD25+CD127dim), mRNA expression,
western blot data, and average integral optical density of
expression of various inflammatory proteins in mouse co-
lonic mucosa among different groups were analyzed by
using one-way ANOVA after post hoc testing.
Table 1 Oligonucleotide primers used in this work






TLR4-F GCTGCAACTGATGTTCCTTCT 95 % N/A N/A
TLR4-R CCCAACATTCATCCATCTCA
NF-κB-F AAAGCCCTGACAGTCCATTG 93 % N/A N/A
NF-κB-R TTGCTAGACACCGTCTGTGC
FOXp3-F TCGAGCTTCCCAGAGAGAGA 94 % N/A N/A
FOXp3-R GGCCCTGACTGGATGTAAGT
PCNA-F AAGAAGAGGAGGCGGTAA 92 % N/A N/A
PCNA-R AGTGTCCCATGTCAGCAA
β-actin-F TTGCTGACAGGATGCAGAAG 94 % N/A N/A
β-actin-R ACATCTGCTGGAAGGTGGAC
GAPDH-F AATGTGTCCGTCGTGGATCT 93 % N/A N/A
GAPDH-R GGTCCTCAGTGTAGCCCAAG
18S-rRNA-F ATTGGAGCTGGAATTACCGC 95 % N/A N/A
18S-rRNA-R CGGCTACCACATCCAAGGAA
Notes: N/A indicates no results be detected
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Results
κ-Carrageenan aggravates weight loss and decrease in
the survival ratio of mice with OXA-induced inflammation
To determine whether pretreatment with κ-carrageenan
affected the damage induced by OXA, weight loss and
survival rates of the mouse models were examined.
Figure 1a reveals that the percent of weight loss on day
1 was significantly different [F (7, 55) = 30.098, P < 0.01].
No significant differences in weight loss between the Blank
group and the carrageenan alone-treated groups on day 1
were detected. The rate of weight loss in mice belonging to
the OXA-treated group was significantly lower than that
observed in Blank group (P < 0.01), which decreased by
about 12 %. Interestingly, pretreatment with κ-carrageenan
aggravated the weight loss. The body weights of mice from
the LOW+OXA, MED+OXA, and HIG +OXA groups
were markedly lower than that of the OXA-treated group
on day 1 (P = 0.048, P = 0.001, and P = 0.047), which de-
creased by about 16.9 %, 21.3 %, and 16.5 % respectively.
Consistent with the observed difference in weight
change, the Blank and carrageenan-treated groups showed
similar survival rates, whereas the OXA-treated mice
showed an 87.5 % survival ratio. The survival ratio of the
carrageenan +OXA group was lower than that of the
OXA-treated groups. Among these, the group that re-
ceived a medial-dose (8.3 mg/kg) κ-carrageenan for
14 days showed a 37.5 % mortality rate, which was the
highest (Fig. 1b), suggesting that medial-dose (8.3 mg/kg)
κ-carrageenan significantly aggravated weight loss and
decreased the survival ratio due to OXA exposure.
Effects of κ-carrageenan on the severity of colonic
damage
Colonic damage scores were significantly higher in
OXA-treated mice compared to those of the Blank
group mice (P < 0.01). Macroscopic analysis indicated
that in the OXA-treated group, inflammation was mainly
localized in the distal part of the colon, which shortened
and thickened, as well as presented signs of colonic
edema and hemorrhagic changes (Fig. 2e).
Carrageenan alone showed no impact on the colons of
animals, wherein the colonic mucosa was apparently
Fig. 1 The effect of κ-carrageenan on body weight and survival ratio of mice with oxazolone-induced colitis. a Weight changes. b Survival ratio.
Mice were treated with different doses of carrageenan, and then intrarectally challenged with 100 μL of 1 % oxazolone. One day after treatment,
the decrease in body weight and the mortality rate of the animals were recorded. Pairwise comparisons between groups at various time points
were conducted by using two-way ANOVA and the LSD post hoc test. *P < 0.05, **P < 0.01, compared with that of the Blank group. #P < 0.05,
##P < 0.01, compared to that of the oxazolone-treated group
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Fig. 2 Effect of κ-carrageenan on colonic damage following oxazolone administration. A representative photograph of the colon encompassing
the cecum to the rectum. a Blank group; b LOW group; c MED group; d HIG group; e OXA group; f LOW+OXA group; g MED +OXA group; h HIG +
OXA group; i Colonic damage scores 1 day after oxazolone administration. The damage scores were evaluated as described in the “Methods” section.
Data are expressed as a column chart. *P < 0.05, **P < 0.01, compared with that of the Blank group. # P < 0.05, ## P < 0.01, compared to that of the
oxazolone-treated group
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normal, and symptoms of congestion, edema, and ero-
sion were not detected (Fig. 2b–d). No significant differ-
ences in colonic macroscopic scores of mice from the
Blank group mice and those of the LOW, MED, and
HIG treatment groups were observed. Figure 2f–h
reveals that OXA-induced colonic damage was markedly
augmented in mice pretreated with different concentra-
tion of carrageenan. The colons were more reddish due
to the production of a bloody stool compared to those
of the OXA-treated mice, suggesting that a more severe
intestinal inflammation had occurred in the LOW+OXA,
MED +OXA, and HIG-OXA-treated mice (Fig. 2f–g).
The colonic damage scores of the LOW+OXA, MED +
OXA, and HIG +OXA groups were higher than that of
the OXA-induced group (P < 0.05, Fig. 2i). Among these,
the MED +OXA group showed the highest score of 3.75.
A 1.55-fold higher colonic damage score was observed in
the MED +OXA group compared to the OXA-treated
group (P < 0.01). These results indicate that carrageenan
can synergistically enhance OXA-induced inflammation.
Effects of κ-carrageenan on the histological changes of
OXA-induced colonic damage
No histological differences in the effect of κ-carrageenan on
OXA-induced colonic damage between the carrageenan-
treated groups and the Blank group were observed. The
colonic tissue of the Blank group showed normal features
such as an adequate number of goblet cells and intact
crypts (Fig. 3a). Figure 3e shows the colonic sections of
OXA-exposed mice with a lower number of goblet cells
and epithelial cells, and an increase in lymphocyte infiltra-
tion, accompanied by a mixed inflammatory infiltrate of
granulocytes, relative to that observed in mice of the Blank
group.
Histological analysis showed that carrageenan was
effective in aggravating OXA-induced colitis (Fig. 3f–h).
The colonic sections from the LOW+OXA, MED +
OXA, and HIG +OXA-treated mice revealed mucosal
inflammation, which was characterized by lymphocyte
cell infiltration, as well as a significant reduction in the
number of goblet cells. A 1.22-fold augmentation in
histologic score was obtained in the LOW+OXA group
(P < 0.05), a 1.32-fold increase in the MED +OXA group
(P < 0.01), and a 1.25-fold increase in the HIG +OXA
group relative to the OXA-treated group (P < 0.05) (Fig. 3i).
Analysis of histological changes of the colon by using
scanning electron microscopy
Intact microvilli, normal epithelial cell surface, and crypts
were observed by scanning electron microscopy in the
Blank group (Fig. 4a). No significant differences in the epi-
thelial mucosa of the colon between the LOW, MED, and
HIG groups and the Blank group were observed, with all
groups showing normal features (Fig. 4b–d). However, at
higher magnification, damage to the epithelial mucosa
surface and disintegration of the microvilli were observed
in the colon of the OXA-treated group (Fig. 4e). Figure 4
shows that carrageenan was effective in aggravating OXA-
induced colonic damage. The histological changes of the
colon were markedly exacerbated in the LOW+OXA,
MED +OXA, and HIG +OXA groups (Fig. 4f–h). Scan-
ning electron microscopy showed more pronounced dam-
age to the epithelial cell surface, disintegration of the
microvilli, excessive mucus secretion at crypt openings,
extensive distribution of ulcers on the colonic surface
were observed in the tissues of mice belonging to the
MED +OXA group (Fig. 4e).
κ-Carrageenan administration promoted the OXA-induced
decrease in the ratio of CD4+CD25+ regulatory T cells
(Tregs)
Treg cells regulate responses of the immune system.
Figure 5 reveals that the ratio of CD4+CD25+/CD4+ in
the peripheral blood of OXA-treated group was sig-
nificantly lower than that observed in the Blank group
(P < 0.01). No apparent effects of different concentra-
tions of κ-carrageenan alone on the proportion of Treg
cells were observed. On the other hand, κ-carrageenan ag-
gravated the decrease in CD4+CD25+/CD4+ cells in the
peripheral blood of OXA-treated mice. A 1.206-fold reduc-
tion in CD4+CD25+/CD4+ was observed in the LOW+
OXA group (P < 0.05) and 1.22-fold decrease in the HIG +
OXA group compared to that of the OXA-treated group
(P < 0.05). The CD4+CD25+/CD4+ ratio of the MED+
OXA group showed 1.49-fold decrease compared to that
of the oxazolone group (P < 0.01). These findings demon-
strate that OXA causes an immune imbalance in mice,
whereas carrageenan augments this imbalance.
κ-Carrageenan promotes cytokine production in
OXA-induced mice colonic inflammation
The levels of seven cytokines in the serum were determined
by flow cytometry by using the Mouse Inflammation Cyto-
metric Bead Array (CBA) assay. Of these cytokines, TNF-α
and IL-6 as classified as pro-inflammatory cytokines; IFN-γ
and IL-2 are Th1 cytokines; IL-4, IL-10 are Th2 cytokines;
and IL-17A is a Th17 cytokine.
Interestingly, administration of carrageenan alone
resulted in the upregulation of the seven cytokines, ex-
cept for IL-17A, but no statistical difference (P > 0.05,
Table 2). However, OXA treatment induced a significant
elevation in the secretion of TNF, IL-6, and IL-10 (P <
0.01). Mice pretreated with medium-dose (8.3 mg/kg) of
carrageenan showed a significant increase in the OXA-
induced production of IL-10, IL-6, and TNF (P < 0.01). Of
the seven cytokines, IL-6 showed the highest increase
(3.82-fold) compared to that of the OXA group (Table 2).
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The expression levels of TLR4, NF-κB, PCNA, and FOXp3
mRNA in the colonic mucosa of experimental mice
No differences in the levels of the four proteins were ob-
served between Blank group and κ-carrageenan alone-
treatment group. However, OXA exposure and induction
of inflammation was associated with a significant in-
crease in the level of mRNA expression of TLR4, NF-κB,
and PCNA in mouse colonic tissues. Carrageenan pre-
treatment resulted in a significant increase in the level of
mRNA expression of TLR4, NF-κB, and PCNA com-
pared to that of the OXA control group. However, a de-
crease in the level of FOXp3 mRNA expression was
observed after OXA treatment (P < 0.01), and pretreat-
ment with different doses of κ-carrageenan with OXA
resulted in a significantly synergistic decreased in the
FOXp3 mRNA expression compared to that of the OXA
group (Fig. 6; P < 0.05).
Synergistic effects of κ-carrageenan on OXA-induced
protein expression in colonic mucosa of experimental
mice
The impact of carrageenan on the expression of TLR4,
NF-κB, and PCNA-protein levels in the colonic mucosa
of experimental mice was immunohistochemically ana-
lyzed. Table 2 shows that κ-carrageenan alone did not
apparently affect the expression of TLR4, NF-κB, and
PCNA in colonic epithelial cells. The expression levels
of TLR4, NF-κB, and PCNA in the colonic epithelium
increased after OXA injection (P < 0.01). Mice pre-
treated with different doses of carrageenan showed a
Fig. 3 Effect of κ-carrageenan on colonic histological changes and colonic histological scores of oxazolone-treated mice. Representative images
of the histological features of the colonic tissue of blank (a Blank group; b LOW group; c MED group; d HIG group; e OXA group; f LOW +OXA
group; g MED +OXA group; h HIG + OXA group. HE: ×200, Higher magnifications of the pictures: ×600). i Histological grading of colitis in oxazolone-
induced mice. Histological grading was determined as described in the “Methods” section. Data are expressed as a histogram plot. **P < 0.01,
compared to that of the Blank group; #P < 0.05, ##P < 0.01, compared to that of the oxazolone-treated group
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significant increase in the OXA-induced expression of
TLR4, NF-κB, and PCNA (P < 0.05). The most signifi-
cant increase in the expression levels of these proteins
was observed in the MED + OXA group. A 1.51-fold
increase in TLR4 expression in colonic mucosa was
detected in the MED + OXA group (P < 0.01), whereas
a 1.14-fold upregulation in NF-κB expression in co-
lonic mucosa was observed in the MED + OXA group
(P < 0.01) and a 1.79-fold increase in PCNA expression
in the MED + OXA group compared to that of the
OXA-treated group was detected (P < 0.01) (Fig. 7,
Table 3).
Table 3 shows that the expression levels of Foxp3
expression in the colonic epithelium decreased after
OXA injection (P < 0.01), whereas carrageenan treatment
significantly decreased the level of OXA-induced expres-
sion of FOXp3 (Fig. 6; Table 3; P < 0.05).
κ-Carrageenan enhances oxazolone-induced activation of
TLR4 and NF-κB in experimental mice
NF-κB is one of the most important transcription factors
that regulate the expression of numerous pro-inflammatory
cytokines. We examined whether κ-CGN enhances
oxazolone-induced NF-κB activation. Figure 8 shows that
treatment with κ-carrageenan alone resulted in a slight
increase in oxazolone-induced TLR4 and nuclear levels of
the p65 subunit of NF-κB. However, oxazolone significantly
increased TLR4 and NF-κB levels (P < 0.01). In addition,
pretreatment with different doses of κ-carrageenan mark-
edly promoted the expression of TLR4 and NF-κB in
oxazolone-stimulated mice. A 1.78-fold increase in TLR4
expression in colonic tissues was detected in the MED+
OXA group (P < 0.01) and a 1.57-fold upregulation in NF-
κB expression in the MED+OXA group compared to that
of the OXA-treated group (P < 0.01) (Fig. 8, Table 3).
Fig. 5 Ratio of CD4 + CD25+/CD4+ regulatory T cells (Tregs) in the peripheral blood of mice. **P < 0.01, compared to that of the Blank group. # P< 0.05,
compared to that of the oxazolone-treated group
Fig. 4 Scanning electron microscopy of histological changes. a Blank group; b LOW group; c MED group; d HIG group; e OXA group; f LOW+OXA
group; g MED +OXA group; h HIG + OXA group. ×200 magnification
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Discussion
Although the FDA and JECFA consider carrageenan as a
safe saccharide [1, 5, 11], studies have shown that it in-
duces ulcerations in animal models, suggests that it
poses a carcinogenic risk to humans [1–3, 27]. This find-
ing has sparked controversy and intense debate, and the
mechanism underlying this pathological condition has
remained uncertain. The present study presents a pos-
sible mechanism of carrageenan that involves an inflam-
matory response.
BALB/c is a mouse strain that is susceptible to OXA-
induced inflammation [24, 28]. In this research, we used
OXA to establish an acute gut inflammation BALB/c
mouse model, which resembles ulcerative colitis in path-
ology and the immune response inof human. It has been
reported that the initial toxic effects of OXA leads to a
flooding of the lamina propria and inducing an increase
in the secretion of Th2 cytokines IL-4 and IL-5, which
in turn leads to further inflammation. [24, 29]. More-
over, rectal instillation of 150 μL of 1 % OXA is enough
to lead to an accelerated inflammation lasting for 1–2
days by a Th2 response in the distal half of the mouse
colon of the mice, thereby resulting in either rapid
recovery or death [24]. Therefore, one day after injection
of OXA was decided as the experimental time to detect
the aggravating effect of carrageenan on the inflamma-
tory response.
The average daily intake of carrageenan in the infant
formula is 0.3 g/L [2], amounting to 240 mg/5.8 kg/day
(≈41.7 mg/kg/day). In the typical Western diet, the daily
intake of carrageenan is considerably more than 500 mg/
60 kg/day (≈8.3 mg/kg/day) [30]. Bhattacharyya et al.
reported that a dose of 50 μg/30 g/day (≈1.7 mg/kg/day)
carrageenan induces colonic inflammation in IL-10-
deficient mice [18]. Therefore, in the present study, we
used these concentrations to investigate the effect of
carrageenan on OXA-induced inflammation.
Here, we first discovered that κ-carrageenan aggravates
OXA-induced inflammation in BALB/c mice by signifi-
cantly increasing weight loss, lethality rate, and degree
of colonic injury. Of particular interest is our finding
that mice pretreated with a medial-dose (8.3 mg/kg) of
κ-carrageenan for 14 days resulted in a 37.5 % of mor-
tality rate, whereas that of OXA-treated control mice
was 12.5 % (Fig. 2). Histological and microscopic evalu-
ation also confirmed that intragastric administration of
Table 2 The levels of the inflammatory cytokines IL-10, IL-17A, TNF, IFN-γ, IL-6, IL-4, and IL-2 in mouse serum (pg/ml, mean ± SEM)
Group IL-10 IL-17A TNF IFN-γ IL-6 IL-4 IL-2
Blank 1.73 ± 0.15 2.31 ± 0.35 3.71 ± 0.20 1.87 ± 0.08 2.61 ± 0.15 1.79 ± 0.11 1.80 ± 0.32
OXA 6.48 ± 1.19 ** 2.94 ± 0.99 10.98 ± 0.78** 1.81 ± 0.38 47.6 ± 2.64 ** 2.34 ± 0.43 2.43 ± 0.09
LOW 3.42 ± 0.45 2.91 ± 1.00 6.18 ± 0.70 2.64 ± 0.44 3.57 ± 0.50 2.33 ± 0.33 2.14 ± 0.28
LOW +OXA 11.34 ± 2.4**# 3.07 ± 0.83 26.62 ± 3.07**## 1.69 ± 0.27 92.32 ± 3.36**# 2.70 ± 0.27* 2.28 ± 0.27
MED 2.27 ± 0.78 2.34 ± 2.08 6.40 ± 0.35 2.58 ± 0.91 4.31 ± 0.55 2.20 ± 0.60 2.08 ± 0.21
MED + OXA 19.67 ± 2.35**## 2.56 ± 0.44 35.0 ± 3.13**## 1.88 ± 0.21 182.17 ± 7.85**## 2.49 ± 0.12** 2.57 ± 0.18
HIG 2.80 ± 0.74 2.07 ± 0.17 5.95 ± 0.75 1.90 ± 0.14 3.64 ± 0.39 2.36 ± 0.68 2.60 ± 0.24
HIG + OXA 12.32 ± 2.57**# 2.56 ± 0.34 30.63 ± 2.83**## 1.61 ± 0.08 107.17 ± 3.74**# 2.66 ± 0.11** 2.16 ± 0.45
Notes: *P < 0.05, compared to that of the blank group. **P < 0.01, compared to that of the blank group. #P < 0.05, compared to that of the oxazolone-treated group.
##P < 0.01, compared to that of the TNBS-treated group
Fig. 6 The impact of κ-carrageenan on the expression of inflammatory response-related proteins in the colonic mucosa of experimental mice.
200× magnification
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κ-carrageenan aggravated OXA-induced inflammation
in BABL/c mice. Of the three doses of κ-carrageenan
used in the present study, the medium dose showed
highest score histological scores. The survival ratio of
the OXA +MED group was also the lowest. It is pos-
sible that the high concentration of carrageenan in-
duces its formation into a gel in the gut of mice, which
in turn reduces its contact without other gut content.
In addition, Weiner et al. also observed that intragastric
administration of a high dose of food-grade carrageen
an just directly affected theresulted in the production
of soft stools or development of diarrhea, which are
common effects of non-digestible high-molecular weight
compounds [31]. Therefore, the aggravated effects of
carrageenan do not appear to respond to a traditional
dose–response curve.
OXA-induced inflammation is often employed in
research investigations on the contribution of the Th2-
dependent immune response to intestinal inflammation
[24]. The present study showed that OXA-induced
inflammation is accompanied by the release of various
inflammatory cytokines, not only Th2 type cytokines
IL-10, but also pro-inflammatory cytokines, TNF-α and
IL-6 [24, 28]. Previous reports have revealed that OXA-
Fig. 7 Effect of κ-carrageenan on the level of mRNA expression of TLR4, NF-κB, FOXp3, and PCNA. Real-time quantitative RT-PCR was used to measure
the level of mRNA expression of TLR4, NF-κB, FOXp3, and PCNA. *P < 0.05, **P < 0.01 relative to that of the Blank group. # P < 0.05, ## P < 0.01 compared
to that of the OXA-treated group
Table 3 Impact of carrageenan on the expression of various proteins in mouse colonic mucosa (Au, mean ± SEM)
Group Negative control TLR4 NF-κB FOXp3 PCNA
Blank 1.57 ± 0.48 6.24 ± 0.48 7.01 ± 0.73 25.97 ± 0.38 5.30 ± 0.24
OXA 1.84 ± 0.31 13.83 ± 0.21** 18.07 ± 0.82** 16.51 ± 0.72** 13.54 ± 0.43**
LOW 2.65 ± 0.19 6.45 ± 0.32 7.8 ± 1.22 24.23 ± 0.58 5.86 ± 0.20
LOW +OXA 2.74 ± 0.23 15.25 ± 0.23**# 20.26 ± 1.40**# 14.24 ± 0.65**# 15.96 ± 0.69**#
MED 2.53 ± 0.28 6.63 ± 0.25 7.95 ± 1.26 24.50 ± 0.75 6.19 ± 0.18
MED + OXA 2.36 ± 0.29 17.61 ± 0.45**## 26.68 ± 0.83**## 6.48 ± 0.68**## 24.41 ± 0.27**##
HIG 2.59 ± 0.23 6.56 ± 0.20 7.33 ± 1.16 24.56 ± 0.75 5.99 ± 0.28
HIG + OXA 77.6 ± 15.3 15.07 ± 0.78**# 21.33 ± 1.90**# 14.18 ± 0.86**# 16.98 ± 1.70**##
Notes: **P < 0.01, compared to that of the Blank group; #P < 0.05, ##P < 0.01, compared to that in the oxazolone-treated group
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induced inflammation is characterized by an upregula-
tion of IL-4 [29]; however, in the present study,
although an increased level of IL-4 expression was ob-
served in the OXA group, this was not statistically sig-
nificant. No increase in the levels of Th1 cytokines
IFN-γ, IL-2, and IL-17 was observed with OXA and κ-
carrageenan treatment. The synergistic effect of κ-
carrageenan on OXA-induced changes is also reflected
in the secretion levels of inflammatory cytokines. The
secretion of pro-inflammatory cytokines TNF-α and IL-
6 in OXA-treated mice were all significantly augmented
by κ-carrageenan pretreatment. These findings suggest
that carrageenan aggravated the OXA-induced inflam-
mation of intestinal tissues.
CD4+CD25+ regulatory T cells (Tregs) can regulate
and suppress the immune response, thus; therefore,
these play an important role in the maintenance of per-
ipheral immune tolerance. The decrease in the number
of Tregs often results in a development of various kinds
of autoimmune disease such as inflammatory bowel dis-
ease (IBD) [32]. The present study showed that the
number of Tregs in the peripheral blood of OXA-treated
group was lower than that of the Blank group, which
further decreased after κ-carrageenan treatment, demon-
strating that OXA can cause an imbalance in the immune
system of mice, and carrageenan augments this imbalance.
FOXp3 is a transcription factor that plays a major role
in the development and maintenance of the immuno-
suppressive function of Tregs [33]. Galitovskiy et al.
observed that the expression of FOXp3 is decreased in
the inflamed areas of ulcerative colitis compared to that
of the normal colon [34]. This finding is consistentin
agreement with the observations of the present study,
wherein the intragastric administration of κ-carrageenan
significantly decreased the OXA-induced mRNA expres-
sion of FOXp3 in the colonic mucosa, indicating that
the suppressor activity of FOXp3 might have been abro-
gated in vivo or was insufficient to counterbalance the
acute mucosal inflammation in OXA-treated mice.
Mice pretreated with different doses of carrageenan
showed a significant increase in the levels of OXA-induced
expression of NF-κB and TLR4. Some studies have demon-
strated that carrageenan upregulated interleukin-8 (IL-8) se-
cretion through TLR4, and activated NF-κB in human
colonic epithelial cells [16, 20]. Benard et al. also observed
that κ-carrageenan induced TNF production via NF-κB acti-
vation [21]. Recently, we have beenare exploring the mech-
anism of underlying the synergistic effect of κ-carrageenan
on lipopolysaccharide (LPS)-induced interleukin-8 (IL-8)
secretion in HT-29 cells. We found that κ-carrageenan pre-
treatment increased LPS-stimulated IL-8 secretion. The
TLR4-NF-κB pathway was activated, as evidenced by the
enhancement of Bcl10 (B-cell CLL/lymphoma 10) expres-
sion, IκBα phosphorylation, and nuclear NF-κB localization
(Wu, wuweixiehou@163.com). These findings demonstrate
that intragastric administration with κ-carrageenan signifi-
cantly activated intestinal inflammation by upregulating
TLR4 and NF-κB in colonic mucosa.
Conclusion
In conclusion, intrarectal injection of OXA in mice causes
colonic damage and inflammation. Treatment of mice with
κ-carrageenan significantly aggravated OXA-induced in-
flammation in BALB/c mice. The results of the present
study suggest that the synergistic effect of κ-carrageenan
might be linked to the induction of an imbalance in the ex-
pression of intestinal inflammatory cytokines, which then
magnified the existing intestinal inflammation. Therefore,
under the intestinal “unhealthy” state, carrageenans may
serve as potential inflammatory agents that impart certain
harmful effects.
Fig. 8 κ-Carrageenan enhanced oxazolone-induced activation of NF-κB. The protein levels of TLR4 and NF-κB p65 were analyzed by western blotting.
The data are presented as the density ratio vs. β-actin. **P < 0.01, compared to that of the Blank group. # P < 0.05, ## P < 0.01, compared to that of the
oxazolone-treated group
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